The Aesthetic Guide is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

AcelRx Announces an Investigator-Initiated Study of DSUVIA in Patients Undergoing Plastic Surgery Procedures

AcelRx Announces an Investigator-Initiated Study of DSUVIA in Patients Undergoing Plastic Surgery Procedures
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an agreement with Newport Plastic and Reconstructive Surgery Associates for an investigator-initiated study analyzing data from the historical use of DSUVIA (sufentanil sublingual tablet 30 mcg) for various same-day plastic surgery procedures. 

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an agreement with Newport Plastic and Reconstructive Surgery Associates for an investigator-initiated study analyzing data from the historical use of DSUVIA (sufentanil sublingual tablet 30 mcg) for various same-day plastic surgery procedures. 

The principal investigator, Dr. Hisham Seify, is a board-certified plastic surgeon and the past-president of the Orange County Society of Plastic Surgeons. The study will focus on the efficacy and safety of DSUVIA for use in general anesthesia plastic surgery cases, and "awake" cosmetic procedures performed at Newport Plastic and Reconstructive Surgery's center. Data from a total of 70 patients will be evaluated for endpoints which will include the utilization of DSUVIA (number of doses, timing of doses), overall amount of opioid utilized, use of other concomitant medications, vital signs, adverse events, length of surgery and time in recovery.  

"We are very interested in analyzing data from patients that were administered DSUVIA across all types of plastic surgery procedures. We have used DSUVIA for over a year in a wide variety of cases and there are no currently published studies focusing on plastic surgery with this sublingual analgesic, which has been a major evolution for our practice," said Dr. Seify. "Evaluating the safety, efficacy, and timing of dosing of DSUVIA for short cases in awake patients, such as liposuction, as well as for more extensive surgeries under general anesthesia, will allow other plastic surgeons to benefit from our experience," continued Dr. Seify.

 

Read more here.

 

Source:

PR Newswire

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish